Management of Pulmonary Sarcoidosis

Initial Assessment and Diagnosis

The clinical presentation of weight loss, fatigue, and physical findings of finger clubbing, along with laboratory findings of elevated serum enzyme levels and radiological features of early interstitial lung disease (ILD) with sarcoidosis changes on high-resolution computed tomography (HRCT), are consistent with pulmonary sarcoidosis with likely systemic involvement, as recommended by the European Respiratory Society 1, 2
The presence of finger clubbing, weight loss, and early ILD suggests a potentially progressive disease course that requires intervention, according to the European Respiratory Society guidelines 1, 2

The European Respiratory Society strongly recommends oral glucocorticoid therapy, such as prednisone, as the initial treatment for pulmonary sarcoidosis with significant involvement, to improve and preserve lung function and quality of life 1, 3
The recommended starting dose is 20 mg once daily of prednisone, as suggested by the European Respiratory Society 4
Treatment should be initiated promptly in patients showing signs of systemic symptoms and early ILD changes, as recommended by the European Respiratory Society 1, 2

Follow-up should be scheduled at 3-6 months after initiating steroid therapy, including monitoring of pulmonary function tests, symptoms assessment, and repeat HRCT to evaluate radiographic response, as recommended by the European Respiratory Review 3
Monitoring should include pulmonary function tests, such as forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), to assess treatment response, as suggested by the European Respiratory Journal 1, 5

After initial response, the dose should be reduced to the lowest dose that provides satisfactory symptom relief and disease control, typically ranging from 5-10 mg once daily to once every other day, as recommended by the European Respiratory Review 3, 4
Treatment duration is often prolonged, with at least half of patients still on treatment 2 years later, according to the European Respiratory Journal 1

Response to treatment should be evaluated based on improvement in pulmonary function tests, reduction in symptoms, radiographic improvement on HRCT, as recommended by the European Respiratory Journal 1, 5

If the patient shows inadequate response to glucocorticoids, consider adding a steroid-sparing agent, such as methotrexate, as recommended by the European Respiratory Review 3, 4
Other options include leflunomide, azathioprine, or mycophenolate mofetil, as suggested by the European Respiratory Journal 4

Glucocorticoid-related side effects must be monitored, including diabetes, hypertension, weight gain, osteoporosis, cataracts, and mood changes, as recommended by the European Respiratory Journal 4
Relapse of symptomatic disease occurs in a significant number of patients upon withdrawal of therapy, necessitating careful tapering and long-term follow-up, according to the European Respiratory Journal 2